BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
BioMarin Pharma (BMRN) Reports In-Line Q4 EPS
February 23, 2022 4:07 PM ESTBioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.32), in-line with the analyst estimate of ($0.32). Revenue for the quarter came in at $449.8 million versus the consensus estimate of $442.09 million.
GUIDANCE:
BioMarin Pharma sees FY2022 revenue of $2.05-2.15 billion, versus the consensus of... More
